SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines.

Martinón-Torres, F; Bosch, X; Rappuoli, R; Ladhani, S; Redondo, E; Vesikari, T; García-Sastre, A; Rivero-Calle, I; Gómez-Rial, J; Salas, A; et al. Martinón-Torres, F; Bosch, X; Rappuoli, R; Ladhani, S; Redondo, E; Vesikari, T; García-Sastre, A; Rivero-Calle, I; Gómez-Rial, J; Salas, A; Martín, C; Finn, A; Butler, R (2019) TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines. Hum Vaccin Immunother, 15 (10). pp. 2405-2415. ISSN 2164-554X https://doi.org/10.1080/21645515.2019.1609823
SGUL Authors: Ladhani, Shamez Nizarali

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (1MB) | Preview

Abstract

The Ninth Interactive Infectious Disease workshop TIPICO was held on November 22-23, 2018, in Santiago de Compostela, Spain. This 2-day academic experience addressed current and topical issues in the field of infectious diseases and vaccination. Summary findings of the meeting include: cervical cancer elimination will be possible in the future, thanks to the implementation of global vaccination action plans in combination with appropriate screening interventions. The introduction of appropriate immunization programs is key to maintain the success of current effective vaccines such as those against meningococcal disease or rotavirus infection. Additionally, reduced dose schedules might improve the efficiency of some vaccines (i.e., PCV13). New vaccines to improve current preventive alternatives are under development (e.g., against tuberculosis or influenza virus), while others to protect against infectious diseases with no current available vaccines (e.g., enterovirus, parechovirus and flaviviruses) need to be developed. Vaccinomics will be fundamental in this process, while infectomics will allow the application of precision medicine. Further research is also required to understand the impact of heterologous vaccine effects. Finally, vaccination requires education at all levels (individuals, community, healthcare professionals) to ensure its success by helping to overcome major barriers such as vaccine hesitancy and false contraindications.

Item Type: Article
Additional Information: © 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Keywords: TIPICO, infectious diseases, infectomics, vaccine hesitancy, vaccines, vaccinomics
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Hum Vaccin Immunother
ISSN: 2164-554X
Language: eng
Dates:
DateEvent
3 June 2019Published
14 February 2019Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
Projects:
Project IDFunderFunder ID
R21AI129486National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
R21AI142337National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
U19AI118610National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
U19AI117873National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
U01AI124297National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
R01AI127658National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
P01AI097092National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
U19AI135972National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
R01 AI141226-01National Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
OPP1084518Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
HHSN272201400008CNational Institute of Allergy and Infectious Diseaseshttp://dx.doi.org/10.13039/100000060
GePEM ISCIII/PI16/01478/Cofinanciado FEDERInstituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
ReSVinext ISCIII/PI16/01569/Cofinanciado FEDERInstituto de Salud Carlos IIIhttp://dx.doi.org/10.13039/501100004587
PubMed ID: 31158041
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/111095
Publisher's version: https://doi.org/10.1080/21645515.2019.1609823

Actions (login required)

Edit Item Edit Item